ATE520025T1 - Test für morbus-parkinson-therapeutika - Google Patents

Test für morbus-parkinson-therapeutika

Info

Publication number
ATE520025T1
ATE520025T1 AT06848996T AT06848996T ATE520025T1 AT E520025 T1 ATE520025 T1 AT E520025T1 AT 06848996 T AT06848996 T AT 06848996T AT 06848996 T AT06848996 T AT 06848996T AT E520025 T1 ATE520025 T1 AT E520025T1
Authority
AT
Austria
Prior art keywords
parkinson
test
parkin
disease therapeutics
disease
Prior art date
Application number
AT06848996T
Other languages
English (en)
Inventor
Jennifer Johnston
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE520025T1 publication Critical patent/ATE520025T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06848996T 2005-12-12 2006-12-12 Test für morbus-parkinson-therapeutika ATE520025T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74996405P 2005-12-12 2005-12-12
PCT/US2006/047515 WO2007089334A2 (en) 2005-12-12 2006-12-12 Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein

Publications (1)

Publication Number Publication Date
ATE520025T1 true ATE520025T1 (de) 2011-08-15

Family

ID=38179819

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06848996T ATE520025T1 (de) 2005-12-12 2006-12-12 Test für morbus-parkinson-therapeutika

Country Status (6)

Country Link
US (2) US20070212679A1 (de)
EP (1) EP1969367B1 (de)
JP (1) JP2009519040A (de)
AT (1) ATE520025T1 (de)
CA (1) CA2632657A1 (de)
WO (1) WO2007089334A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632657A1 (en) * 2005-12-12 2007-08-09 Elan Pharmaceuticals, Inc. Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
US8017348B1 (en) 2005-12-12 2011-09-13 Elan Pharma International Limited Assay for Parkinson's Disease therapeutics
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
WO2009099896A1 (en) * 2008-01-31 2009-08-13 Elan Pharmaceuticals, Inc. Thermal denaturation screening assay to identify candidate compounds for prevention and treatment of parkinson's disease
CA2731704A1 (en) * 2008-07-25 2010-01-28 Progenra Inc. Methods of identifying modulators of ubiquitin ligases
ES2418459B1 (es) * 2008-10-09 2014-08-12 Universitat Autònoma De Barcelona Relacionando agregación proteica con supervivencia de levadura
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
JP5694345B2 (ja) 2009-10-22 2015-04-01 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体の調節因子
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ, インコーポレイテッド Hivを治療するためのトール様受容体の調節因子
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
JP6814991B2 (ja) * 2016-02-01 2021-01-20 学校法人順天堂 パーキン活性化剤のスクリーニング法
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
EP1262557B1 (de) * 2000-02-24 2006-10-18 Boehringer Ingelheim International GmbH Das parkin-protein als ubiquitinligase
US20040198650A1 (en) * 2001-03-29 2004-10-07 Poul Jensen Means for inhibiting proteolytical processing of parkin
JP2003018992A (ja) * 2001-06-28 2003-01-21 Inst Of Physical & Chemical Res Pael受容体、Pael受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
US7070940B2 (en) * 2002-07-18 2006-07-04 Aventis Pharma S.A. Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
CA2632657A1 (en) * 2005-12-12 2007-08-09 Elan Pharmaceuticals, Inc. Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein

Also Published As

Publication number Publication date
EP1969367B1 (de) 2011-08-10
WO2007089334A3 (en) 2008-01-10
CA2632657A1 (en) 2007-08-09
US20070212679A1 (en) 2007-09-13
US20090317825A1 (en) 2009-12-24
EP1969367A2 (de) 2008-09-17
JP2009519040A (ja) 2009-05-14
WO2007089334A2 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
MX358705B (es) Agentes de union de esclerostina.
EA021222B8 (ru) Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
ATE520025T1 (de) Test für morbus-parkinson-therapeutika
DE60135498D1 (de) Produktion von ganzen Antikörpern in prokaryontischen Zellen
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
MA30474B1 (fr) Formulations de molecule peptide(s) -anticorps therapeutique lyophilisee.
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
MA29836B1 (fr) Proteines de fusion avec l'albumine
BRPI0516857A (pt) dispositivos biomédicos que contêm copolìmeros de bloco anfifìlico
NO20043245L (no) Bindingsproteiner som biosensorer
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
ATE485359T1 (de) Verwendung von grenzflächenaktiven, nicht- enzymatischen proteinen für die textilwäsche
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
MX2007007259A (es) Inhibidores de homodimerizacion de myd88.
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
ATE306498T1 (de) Von zellen präsentierte peptide
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
ATE497976T1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren
EP1963506A4 (de) Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
BR122018077204B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties